2152 citations
,
November 2013 in “Urologia Internationalis” This study reviews the significant prevalence of organic etiologies, especially vascular causes, in erectile dysfunction among men under 40 and emphasizes thorough evaluation and consideration of treatment options like exercise and PDE-5 inhibitors.
218 citations
,
December 2011 in “Advances in Urology” This review discusses the biochemical properties and clinical significance of 5 alpha-reductase isozymes and reports no new clinical results.
9 citations
,
July 2011 in “The Journal of Sexual Medicine” This article examines 5 alpha-reductase inhibitors and their link to persistent sexual dysfunction, but it reports no new clinical findings.
185 citations
,
March 2011 in “The Journal of Sexual Medicine” This study found that 94% of healthy men reported low libido and 92% reported erectile dysfunction as persistent sexual side effects after using finasteride for male pattern hair loss, with these effects lasting on average 40 months post-discontinuation.
223 citations
,
December 2010 in “The Journal of Sexual Medicine” This review discusses persistent adverse effects of 5α‐reductase inhibitors, like diminished libido and erectile dysfunction, in some patients and highlights the need for patient discussions before therapy, especially for androgenetic alopecia.
152 citations
,
October 2010 in “Archives of Dermatology” This study found that daily oral finasteride may increase hair count and improve hair appearance assessments in men with androgenetic alopecia, but it also appears to raise the risk of sexual dysfunction.
33 citations
,
January 2009 in “Journal of Cutaneous and Aesthetic Surgery” This study found no clear evidence that finasteride negatively affects erectile function, though it does cause a reduction in ejaculatory volume and has potential implications for prostate cancer risk.
78 citations
,
December 2008 in “The Journal of Sexual Medicine” This review highlights that sexual dysfunction associated with 5-alpha-reductase inhibitors is recognized in clinical literature, with erectile dysfunction being the most common adverse effect, followed by ejaculatory dysfunction and decreased libido.
31 citations
,
September 2008 in “International Journal of Andrology” This review examined studies on erectile dysfunction and 5 alpha-reductase inhibitors, concluding that these drugs do not significantly cause erectile dysfunction and emphasizing testosterone's importance over dihydrotestosterone in erectile function.
225 citations
,
July 2007 in “The Journal of Sexual Medicine” In this study, patients informed about finasteride's potential sexual side effects reported a significantly higher occurrence of these side effects, suggesting a nocebo effect.
195 citations
,
February 2007 in “The Journal of Clinical Endocrinology and Metabolism” In this study, administering 5alpha-reductase inhibitors reduced dihydrotestosterone levels and was associated with mild, reversible decreases in semen parameters in healthy men.
44 citations
,
July 2004 in “Archives of Dermatology” In this study, treatment with 1 mg of finasteride was associated with stable sexual function, suggesting that sexual side effects may be less common than indicated in clinical trials.
56 citations
,
April 1998 in “Steroids” Finasteride reduces hair loss and treats BPH without major hormone changes, but may cause sexual dysfunction.
15 citations
,
June 1995 in “The Journal of Clinical Endocrinology and Metabolism” This study found that finasteride significantly reduced dihydrotestosterone levels but did not provide clear evidence of impaired libido or erectile function compared to placebo in men.
1040 citations
,
October 1992 in “The New England Journal of Medicine” In this study, 5 mg of finasteride per day significantly improved urinary symptoms and reduced prostate volume in men with benign prostatic hyperplasia, but increased the risk of sexual dysfunction.